N
Numerion Labs
The first deep learning neural network for structure based drug design and discovery
About Numerion Labs
Atomwise is a startup that operates in the pharmaceutical industry, leveraging artificial intelligence (AI) to revolutionize drug discovery. The company's primary offering is an AI engine that uses machine learning and convolutional neural networks to sift through vast chemical libraries. This technology enables Atomwise to identify new small molecule medicines more efficiently and effectively than traditional methods.
The company's clients are primarily in the healthcare and pharmaceutical sectors, who are looking for more efficient ways to discover new drugs. Atomwise's business model is based on developing and co-developing pipeline assets, which are then backed by investors. This means that the company makes money by creating and improving medicines, and then selling these discoveries to pharmaceutical companies or healthcare providers.
Atomwise's unique selling point is its combination of AI and machine learning, which allows it to create better medicines faster. This not only reduces the time and cost associated with drug discovery, but also has the potential to improve patient outcomes by delivering more effective treatments.
In conclusion, Atomwise is a forward-thinking startup that is using AI to disrupt the traditional drug discovery process. Its innovative approach has the potential to make a significant impact on the pharmaceutical industry and improve the lives of patients worldwide.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2012
- Headquarters
- San Francisco, United States
- Employees
- 20
- Open positions
- None listed
- Dealroom signal
- 62.4/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Core AI, Synthetic Biology, Spinout, Tech for Biotech and Pharma, AI Drug Discovery, AI Applications, YC W15, DT and LS, science-based
- Business model
- Manufacturing
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| PRIVATE PLACEMENT NON VCOther financing | Aug 2022 | $20M | — | Sanofi | ↗ |
| GRANTOther financing | Oct 2020 | $2.3M | — | Bill & Melinda Gates Foundation | — |
Growth signals
Latest recorded traffic for Numerion Labs is 7.2K monthly website visits, up 118.2% over the last three months. Numerion Labs's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed10 investors entered at this stage
Grand Challenges Canada
Y Combinator
Khosla Ventures
David E. Weekly
Draper Associates
Farzad (Zod) Nazem
Mission and Market
OS Fund
AME Cloud Ventures
Bill & Melinda Gates Foundation
Series A8 investors entered at this stage
Monsanto
Dolby Family Ventures
DFJ Growth
B Capital
Baidu Ventures
Sanabil
Tencent
DCVC
Other known investors3 additional known investors
Creative Destruction Lab
Sanofi
University of Toronto
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Numerion Labs on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Numerion Labs’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.